Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-75229414 in Metastatic Castration-Resistant Prostate Cancer
NCT05022849Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-75229414 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events, Number of Participants with AEs by Severity and 1 more. Started Sep 2021; status: completed.
02
Drugs
JNJ-75229414
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05022849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022849.